Search Results - lymphoma

2 Results

Sort By:

Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics

SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...

Published: 2/24/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Therapy for T-Cell Lymphoma

NU2022-104 INVENTORS Jaehyuk Choi* Jay Daniels Jurgen Ruland Tim Wartweig SHORT DESCRIPTION Targeting PD-1 related mechanisms for treatment of aggressive T-Cell lymphomas BACKGROUND T-cell non-Hodgkin lymphomas (T-NHLs) are highly aggressive cancers that can be resistant to chemotherapies. The molecular pathogenesis of these cancers remains...

Published: 12/15/2025 | Inventor(s):

Keywords(s): Cancer/Oncology, Lymphoma, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics